AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00857857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086X
Description: Investigational product
Study NCT00857857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP
Description: Positive control
Study NCT00857857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo control
Study NCT03125551 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ginger
Description: Ginger dosage at daily recommended allowance
Study NCT03125551 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garlic
Description: Garlic dosage at daily recommended allowance
Study NCT03125551 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo Biloba
Description: Ginkgo Biloba dosage at daily recommended allowance
Study NCT03125551 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ginseng
Description: Ginseng dosage at daily recommended allowance
Study NCT03125551 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dosage strategy
Study NCT04266054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Storytelling Intervention
Description: 12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
Study NCT01925547 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micellar curcumin
Description: 80 mg micellar curcumin (oral) three times a day for six weeks
Study NCT01925547 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Only the excipients (without curcumin) used to prepare the curcumin micelles are given as placebo.
Study NCT01932333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813 50 mg
Description: Cohort 1: Participants will receive 50 mg of JNJ-40411813 (2 capsules X 25 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
Study NCT04436172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: The spinal anesthesia was given by a trained anesthetist in an equipped room, after all aseptic measures. A 20 gauge intravenous cannula was inserted for maintaining a peripheral line and 0.9% normal saline was used for loading the patient. The pulse and blood pressure were monitored non-invasively. The median approach was utilized and intrathecal space was accessed via 25 gauge Quiincke bevel(Becton Dickinson/Pakistan ) through L4-L5. A block was performed by using 5 mg hyperbaric bupivacaine (Abocain 0.5%/Abbot) after ensuring swirling. Block height was monitored via pinprick test after every three minutes, for 20 minutes until there was no progression. The couple was left alone. The couples received prior training and were explained precautions.
Study NCT01356446 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implementation surgical checklist
Description: a checklist according to the suggestions raised by the WHO is implemented
Study NCT01646606 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent oxygen monitoring
Description: Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. The nurse will attach the probe to the electrical cord which is connected to the monitor. For each measurement, the duration of monitoring will be until a steady wave form is present on the oxygen saturation monitor, indicating a reliable measurement (consistent with current standard of practice). The nurse will document the maximum and minimum reading during the period. The nurse will detach the probe from the electrical cord, leaving the probe attached to the child. Hence, the child's probe will be attached to the electrical cord intermittently as well.
Study NCT01646606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous oxygen monitoring
Description: Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Every 4 hours the nurse will complete and document a set of vital sign measurements, including oxygen saturation level, in keeping with current clinical practice. The reading will be displayed on the bedside monitor in the participants' room. At the completion of vital signs measurement, the nurse will not detach the electrical cord from the probe. Hence, the child's probe will be attached to the electrical cord continuously as well.
Study NCT03521141 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine patch
Description: FDA-approved smoking cessation pharmacotherapy
Study NCT03521141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: FDA-approved smoking cessation pharmacotherapy
Study NCT03521141 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline
Description: FDA-approved smoking cessation pharmacotherapy
Study NCT04203082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Intervention
Description: Single session intervention of psychoeducation + exposure treatment to the operating room and procedural steps of a cesarean delivery
Study NCT03662438 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prescription of a Portable Oxygen Concentrator (POC) device
Description: Participants will be prescribed a lightweight Portable Oxygen Concentrator (POC) device \[Philips SimplyGo Mini\] to be used during exercise and when going into the community setting. Familiarisation and training on the usage of the device will also be provided in conjunction with the home-based physiotherapy program.
Study NCT03521141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: FDA-approved smoking cessation pharmacotherapy
Study NCT04203082 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Standard of care for education about the cesarean /delivery planning varies across the two hospitals. At Children's Hospital Colorado, anesthesiologists are included in the delivery planning meetings where the patients have the opportunity to review anesthetic technique and ask questions.
Study NCT04185233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Games on an iPad
Description: Many games will be programmed on the iPad and organized by age. The child will choose one game and play it during all the procedure time.
Study NCT04185233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: Nitrous oxide will be provided to the child by a mask 3 minutes before the intervention and during all this one.
Study NCT01611142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KW-0761 (mogamulizumab)
Description: 1 mg/kg administered intravenously weekly x 4 then every other week until progression
Study NCT01144858 — intervention group
Intervention type: OTHER
Intervention: a complete transesophageal echocardiography
Description: All patients were evaluated by a complete transesophageal echocardiography with multiplane probes with a 7-MHz transducer before catheter ablation .LA appendage flow was obtained by placing the pulsed Doppler sample volume at the orifice of the LA appendage, after which peak flow velocities were measured and averaged within each RR interval of 10 consecutive cardiac cycles
Study NCT01348074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double dose
Description: For each individual the dose on Day 1 and Day 2 will be twice the one normally taken
Study NCT03538496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.25% Inj
Description: Single shot 20 ml 0.25 bupivacaine
Study NCT01932333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813 100 mg
Description: Cohort 2: Participants will receive 100 mg of JNJ-40411813 (1 capsule X 100 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
Study NCT03521141 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine metabolism
Description: Information on nicotine metabolism will be used to inform selection of medication.
Study NCT03521141 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genetically-informed lung cancer risk score
Description: This intervention uses information from a person's genes and smoking and family medical histories to estimate lung cancer risk compared to current smokers.
Study NCT03521141 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NCI Clearing the Air
Description: A booklet-led intervention designed by the NCI to support cessation at any stage of a quitter's journey, whether they are still thinking about quitting, have made the decision to quit, or have already taken steps to quit and just need help maintaining their new lifestyle.
Study NCT03521141 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NCI Clearing the Air
Description: A booklet-led intervention designed by the NCI to support cessation at any stage of a quitter's journey, whether they are still thinking about quitting, have made the decision to quit, or have already taken steps to quit and just need help maintaining their new lifestyle.
Study NCT01932333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cohort 1: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2; Cohort 2: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2.
Study NCT04550143 — intervention group
Intervention type: OTHER
Intervention: Diaphragm ultrasound (DUS)
Description: DUS assessments of diaphragmatic thickness (TDI), thickness fraction (TFDI) and shear modulus (SMDI), this last measured by shear-wave elastography (SWE), will be performed for both right and left hemi-diaphragms.~A landmark between the 8th and 10th intercostal space in the mid-axillary or antero-axillary line, 0.5-2 cm below the costophrenic sinus, will be used. Here, the diaphragm can be seen as the less echogenic structure between two echogenic lines; TDI (cm) will be the calculated as the distance between the two lines at the end of expiration and TFDI as the rate of change between end-expiration and end-inspiration thicknesses (TFDI = thickness at end inspiration - thickness at end-expiration / thickness at end-expiration, %).~SMDI will assess muscle's stiffness. For each image, a region of interest covering the widest possible surface of diaphragm and allowing an acquisition frequency of 2Hz will be set; results will be retrieved in kilopascals (kPa).
Study NCT04550143 — intervention group
Intervention type: OTHER
Intervention: Peripheral Muscle Ultrasound (PMUS)
Description: PMUS assessments of quadriceps rectus femoris (RF) muscle cross-sectional area (CSARF), echogenicity (ECHORF) and shear modulus (SMRF), this last measured by shear-wave elastography (SWE), will be performed.~Probe will be placed perpendicularly to the anterior plane of the thigh, in 2 anatomical points, as follows:~(i) in the midpoint between the anterior superior iliac spine and the upper pole of the patella and (ii) the border of the lower 1/3 and upper 2/3 between the anterior superior iliac spine and the upper pole of the patella.~CSARF (cm2) will be calculated by outlining the area under the muscle hyperechoic line (aponeurosis). For ECHORF (differences in grey-scale images), the analysis of a region of interest (ROI) of 2cm x 2cm will be performed.~For SMRF (kPa), a ROI covering the widest possible area of the RF and allowing an acquisition frequency of 2Hz will be set for analysis.~All assessments will be performed with minimal compression and a copious amount of water-gel.
Study NCT01433562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1425
Description: DLBS1425 capsule 150 mg thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
Study NCT01433562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DLBS1425
Description: Placebo DLBS1425 capsule thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
Study NCT00666224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate (DB)
Description: Double blind period (DB): glatiramer acetate (GA) by subcutaneous injection, 20mg, once daily, for up to 36 months or until conversion to clinically definite multiple sclerosis (CDMS).
Study NCT00666224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blind period (DB): subcutaneous injection of placebo, once daily, for up to 36 months or until conversion to CDMS
Study NCT00666224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate (OL)
Description: Open label period (OL): glatiramer acetate (GA), 20 mg, subcutaneous injection, once daily, given for up to an additional 24 months.
Study NCT00666224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glatiramer Acetate (OL)
Description: Open label period (OL): glatiramer acetate (GA), 20 mg, subcutaneous injection, once daily, given for up to an additional 24 months.
Study NCT02411435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB
Description: CAB 30 mg as 1 tablet will be administered orally with 240 mL of water in the fasted state.
Study NCT02411435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIF
Description: RIF 600 mg as 2 capsules of 300 mg will be administered orally with 240 mL of water in the fasted state.
Study NCT03066414 — intervention group
Intervention type: PROCEDURE
Intervention: echography
Description: The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
Study NCT02809339 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Study NCT03808012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Braking performance in a brake simulator
Description: Braking performance is tested in a real middle size car cabin to simulate ergonomic conditions of driving a car. This testing cabin has been equipped with customised equipment to allow measurement of reaction time, foot transfer time, brake response time and brake force.
Study NCT02678507 — intervention group
Intervention type: OTHER
Intervention: Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)
Study NCT02454777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo HIT
Study NCT02454777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02454777 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02454777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02454777 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02454777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02454777 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04550143 — intervention group
Intervention type: OTHER
Intervention: Airway occlusion pressure (P0.1)
Description: P0.1 is the pressure developed in the occluded airway 100 milliseconds after the onset of inspiration. Its use doesn't require any additional equipment since it can be easy measured by using patient's ventilator.~For the measurement itself, patients will be in semi-recumbent position (head elevation between 30° and 45°) with knee extended in neutral position and will be asked to stay as relaxed as possible. After 5 minutes breathing without any interruption or disturbance, 4 measurements will be observed and recorded as displayed on the ventilator screen.
Study NCT04550143 — intervention group
Intervention type: OTHER
Intervention: Medical Research Council (MRC) sum score
Description: This is a manual muscle strength testing tool, used very often in the ICU setting. It's based on the assessment of the following muscle groups: shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, and dorsiflexion of the ankle, all scored bilaterally. Muscle strength is graded as follows: 0, no visible/palpable contraction; 1, visible/palpable contraction without movement of the limb; 2, movement of the limb, but not against gravity; 3, movement against gravity; 4, movement against gravity and some resistance; 5, normal.~The sum score ranges between 0 and 60 (between 0 and 5, in 12 muscle groups), with a score \<48 indicating the presence of weakness.
Study NCT04768543 — intervention group
Intervention type: DEVICE
Intervention: Upper airway stimulation (Inspire Medical Systems, Inc.)
Description: phasic hypoglossal nerve stimulation device
Study NCT02041338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin
Study NCT02041338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02041338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin and Paclitaxel
Study NCT03749720 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample taken from cervical cancer patients at time of diagnosis (baseline) and follow-up visits.
Study NCT04345315 — intervention group
Intervention type: OTHER
Intervention: serological test
Description: serological test assessing IgM and IgG directed against SARS-CoV-2
Study NCT01556529 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: risk profile information
Description: (1) patient on a regular basis receives individualized reports on his/her quantitative risk for 6 typical diabetes complications over the next 10 years, (2) standard T2DMP care, as outlined by AWMF diabetes guidelines
Study NCT02356770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collagen Matrix 10808
Description: At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Collagen Matrix 10808 will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
Study NCT02356770 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Connective tissue graft
Description: At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Connective tissue graft (Gold Standard) will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
Study NCT04345315 — intervention group
Intervention type: OTHER
Intervention: Rapid molecular test
Description: Molecular test to detect SARS-CoV-2 in oro/rhinopharyngeal swab
Study NCT01556529 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard DMP care
Description: standard disease management of T2DM care
Study NCT01556529 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard DMP care
Description: standard disease management of T2DM care
Study NCT03950518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsules
Description: Anlotinib Hydrochloride Capsules, 12mg/d
Study NCT03950518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine hydrochloride
Description: AHC,12mg/d AH,40g/d
Study NCT03950518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levamisole
Description: AHC,12mg/d AH,40mg/d LM,150mg/d
Study NCT03688672 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Apioc Contact Lens Design
Description: Novel soft contact lens design.
Study NCT00829296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebivolol
Description: Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached
Study NCT00829296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached
Study NCT01689883 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Current stimulator
Description: This is a device developed by the investigators to produce sub-sensory electrical stimulation delivered via subcutaneous electrodes placed on the skin.
Study NCT01963741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leukotriene D4
Description: Nasal challenge using 16% ethanol diluent, the concentration of which corresponded to the highest concentration of LTD4, was undertaken for exclusion of subjects hypersensitive to ethanol or saline. The LTD4 challenge could be initiated provided that NAR increase was \<30%. Ranges of 4 to 16 mcg.mL-1 LTD4 diluents were applied for a double-fold increment approach at intervals of 6 minutes.